Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.

ABSTRACT: Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease^1-4. Treatment generally requires the administration of high doses of these monoclonal antibodies and has limited efficacy in preventing disease complications or mortality among hospitalized patients with COVID-19⁵. Here we report the development and evaluation of anti-SARS-CoV-2 monoclonal antibodies with optimized Fc domains that show superior potency for prevention or treatment of COVID-19. Using several animal disease models of COVID-19^6,7, we demonstrate that selective engagement of activating Fcγ receptors results in improved effi

SUBMITTER: Yamin R 

PROVIDER: S-EPMC9038156 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature